Arrivo BioVentures is a privately-held biopharmaceutical company focused on accelerating and developing biologics and small molecules through clinical development that have the potential to improve patient lives.
Visit Site
Visit Site
Location: United States, North Carolina, Morrisville
Employees: 11-50
Total raised: $94M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Rex Health... | rexhealthv... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.11.2023 | Series B | $45M | - |
| 25.05.2016 | - | $49M | - |
Mentions in press and media 4
| Date | Title | Description |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 29.11.2023 | Arrivo BioVentures Raises $45M in Series B Financing | Arrivo BioVentures, a Morrisville, NC-based biopharmaceutical company, raised $45M in Series B funding. The round, which brought the total amount to $100M, was led by Orlando Health Ventures with participation from Solas BioVentures Emergin... |
| 25.05.2016 | Drug Development Company Arrivo BioVentures Launches with $49M in Capital | Morrisville, N.C.-based Arrivo BioVentures, a drug development company, launched with the closing of a $49m financing in committed capital. The round was led by Jazz Pharmaceuticals with participation from Solas BioVentures Fund I, L.P., Re... |
| - | Arrivo BioVentures LLC | “ARRIVO has a portfolio of diverse late-stage drug candidates through partnering with investors, innovators, and pharmaceutical companies.” |